Orion Oyj header image

Orion Oyj

ORNAV

Equity

ISIN FI0009014369 / Valor 2553360

NASDAQ Helsinki Ltd, Equities (2024-11-20)
EUR 44.30-0.11%

Orion Oyj
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Orion Oyj is a pharmaceutical company that places a strong emphasis on partnerships and networking throughout its value chain. The company collaborates with other organizations in various areas such as research and development, manufacturing, and marketing of products on a global scale. This approach allows Orion to leverage the expertise and resources of its partners to enhance its operations and expand its reach in the pharmaceutical industry.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (20.08.2024):

Net Sales Growth

Orion Oyj reported net sales of EUR 636.7 million for the first half of 2024, reflecting a 12.2% increase compared to EUR 567.5 million in the same period of 2023. This growth was driven by strong performance in key product lines, including Nubeqa® and Easyhaler®.

Operating Profit Increase

For the first half of 2024, Orion Oyj's operating profit rose to EUR 121.8 million, marking a 19.5% increase from EUR 102.0 million in the first half of 2023. The increase in operating profit was attributed to higher sales and effective cost management across the company's business divisions.

Basic Earnings Per Share

Orion Oyj's basic earnings per share for the first half of 2024 were EUR 0.68, up 19.2% from EUR 0.57 in the same period of the previous year. This improvement in earnings per share reflects the company's robust financial performance and profitability.

Cash Flow from Operating Activities

Cash flow from operating activities per share for Orion Oyj in the first half of 2024 was EUR 0.98, a significant increase compared to EUR 0.27 in the first half of 2023. This substantial rise indicates improved operational efficiency and cash generation capabilities.

Upgraded Financial Outlook

Following the strong performance in the first half of 2024, Orion Oyj upgraded its financial outlook for the full year. The company now estimates net sales to be between EUR 1,440 million and EUR 1,480 million, and operating profit to range from EUR 350 million to EUR 380 million, up from the previous estimates of EUR 1,340 million to EUR 1,410 million in net sales and EUR 280 million to EUR 310 million in operating profit.

Summarized from source with an LLMView Source

Key figures

18.9%1Y
21.2%3Y
10.5%5Y

Performance

23.6%1Y
29.4%3Y
29.2%5Y

Volatility

Market cap

1538 M

Market cap (USD)

Daily traded volume (Shares)

2,308

Daily traded volume (Shares)

1 day high/low

44.7 / 44.1

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Tilray Brands Inc
Tilray Brands Inc Tilray Brands Inc Valor: 42386407
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.53%USD 1.29
GeneDx Holdings Corp
GeneDx Holdings Corp GeneDx Holdings Corp Valor: 126808031
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.34%USD 69.38
Kenvue Inc
Kenvue Inc Kenvue Inc Valor: 124280948
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.38%USD 23.78
ACELYRIN INC
ACELYRIN INC ACELYRIN INC Valor: 126441937
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-6.14%USD 4.43
KK GNI Group
KK GNI Group KK GNI Group Valor: 3303570
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.76%JPY 2,785.00
Herbalife Ltd
Herbalife Ltd Herbalife Ltd Valor: 2002103
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
8.65%USD 8.41
Stride Inc
Stride Inc Stride Inc Valor: 58406765
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.12%USD 102.80
Gyre Therapeutics Inc
Gyre Therapeutics Inc Gyre Therapeutics Inc Valor: 130270397
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.08%USD 12.91
Galderma Group Ltd
Galderma Group Ltd Galderma Group Ltd Valor: 133539272
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.01%CHF 85.95
KK Suzuken
KK Suzuken KK Suzuken Valor: 250303
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.52%JPY 4,850.00